EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Preventing Allogeneic Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial

Hayley T Dillon iD, Nicholas J Saner iD, Tegan Ilsley, David S Kliman iD, Stephen J Foulkes iD, Christian J Brakenridge iD, Andrew Spencer iD, Sharon Avery iD, Piet Claus iD, David W Dunstan iD, Robin M Daly iD, Steve F Fraser iD und 5 weitere

Circulation · 2025

DOI: 10.1161/circulationaha.124.070709 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2025. Verfasst von Hayley T Dillon und 16 weiteren Autor:innen. Beteiligte Einrichtung: Baker Heart and Diabetes Institute, Melbourne, Australia (H.T.D., N.J.S., T.I., C.J.B., D.W.D., N.O., B.M.L., E.J.H.). Hauptthemen laut MEDLINE: Cardiovascular Diseases, Exercise Therapy, Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. We conducted a randomized controlled trial testing whether a multicomponent activity intervention could attenuate reductions in cardiorespiratory fitness and exercise cardiac function (co-primary end points) in adults undergoing allo-SCT. METHODS: Sixty-two adults scheduled for allo-SCT were randomized to a 4-month activity program (activity; n=30) or usual care (UC; n=32). Activity comprised a multicomponent exercise training (3 days.week -1 ) and sedentary time reduction (≥30 minutes.day -1 ) program and was delivered throughout hospitalization (≈4 weeks) and for 12 weeks after discharge. Physiological assessments conducted before admission and at 12 weeks after discharge included cardiopulmonary exercise testing to quantify peak oxygen uptake ( V ˙ o 2 p e a k ), exercise cardiac magnetic resonance imaging for peak cardiac (CI peak ) and stroke volume (SVI peak ) index, echocardiography-derived left ventricular ejection fraction and global longitudinal strain, and cardiac biomarkers (cTn-I [troponin-I] and BNP [B-type natriuretic peptide]). RESULTS: Fifty-two participants (84%) completed follow-up (25 activity and 27 UC); median (interquartile range [IQR]) adherence to the activity program was 74% (41%–96%). There was a marked decline in V ˙ o 2 p e a k in the UC program (−3.4 mL‧kg -1 ‧min -1 [95% CI, −4.9 to −1.8]) that was attenuated with activity (−0.9 mL‧kg -1‧ min -1 [95% CI, −2.5 to 0.8]; interaction P =0.029). Activity preserved exercise cardiac function, with preservation of CI peak (0.30 L‧min -1 ‧m -2 [95% CI, −0.34 to 0.41]) and SVI peak (0.6 mL.m -2 [95% CI, −1.3 to 2.5]), both of which declined with UC (CI peak , −0.68 L‧min -1 ‧m -2 [95% CI, –1.3 to −0.32]; interaction P =0.008; SVI peak , −2.7 mL.m -2 [95% CI, −4.6 to −0.9]; interaction P= 0.014). There were no treatment effects of activity on cardiac biomarkers or echocardiographic indices. CONCLUSIONS: Intervening during and after allo-SCT with a multicomponent activity program during and after allo-SCT is beneficial for preserving a patient’s cardiorespiratory fitness and exercise cardiac function. These results may have important implications for cardiovascular morbidity and mortality after allo-SCT. REGISTRATION: URL: https://anzctr.org.au/ ; Unique identifier: ACTRN12619000741189.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesExercise TherapyStem Cell TransplantationHematopoietic Stem Cell TransplantationHumansMaleFemaleMiddle AgedAdultTransplantation, HomologousCardiorespiratory FitnessAgedExercise ToleranceStroke VolumeTreatment OutcomeQuality of Life

Stichwörter der Autor:innen

cardiac imaging techniquescardio-oncologycardiorespiratory fitnesscardiotoxicityexercisehematologic neoplasmsprimary prevention

Autor:innen und Institutionen

  • Baker Heart and Diabetes Institute, Melbourne, Australia (H.T.D., N.J.S., T.I., C.J.B., D.W.D., N.O., B.M.L., E.J.H.).
  • Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, VIC, Australia (H.T.D., D.W.D., R.M.D., S.F.F.).
  • Institute for Health and Sport, Victoria University, Melbourne, Australia (N.J.S.).
  • Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia (T.I.).
  • Department of Haematology, Royal North Shore Hospital, Sydney, Australia (D.S.K.).
  • Heart, Exercise and Research Trials (HEART) Lab, St Vincent's Institute (S.J.F., A.L-G.), Fitzroy, VIC, Australia.

ORCID-Profile: Hayley T Dillon, Nicholas J Saner, David S Kliman, Stephen J Foulkes, Christian J Brakenridge, Andrew Spencer, Sharon Avery, Piet Claus, David W Dunstan, Robin M Daly, Steve F Fraser, Neville Owen, Brigid M Lynch, Bronwyn A Kingwell, Andre La Gerche, Erin J Howden

Zitieren

APA

Dillon, H. T., Saner, N. J., Ilsley, T., Kliman, D. S., Foulkes, S. J., Brakenridge, C. J., Spencer, A., Avery, S., Claus, P., Dunstan, D. W., Daly, R. M., Fraser, S. F., Owen, N., Lynch, B. M., Kingwell, B. A., La Gerche, A., & Howden, E. J. (2025). Preventing Allogeneic Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial. Circulation. https://doi.org/10.1161/circulationaha.124.070709

Vancouver

Dillon HT, Saner NJ, Ilsley T, Kliman DS, Foulkes SJ, Brakenridge CJ, et al. Preventing Allogeneic Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial. Circulation. 2025. doi:10.1161/circulationaha.124.070709

BibTeX
@article{Dillon2025,
  author = {Dillon, Hayley T and Saner, Nicholas J and Ilsley, Tegan and Kliman, David S and Foulkes, Stephen J and Brakenridge, Christian J and Spencer, Andrew and Avery, Sharon and Claus, Piet and Dunstan, David W and Daly, Robin M and Fraser, Steve F and Owen, Neville and Lynch, Brigid M and Kingwell, Bronwyn A and La Gerche, Andre and Howden, Erin J},
  title = {Preventing Allogeneic Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial},
  journal = {Circulation},
  year = {2025},
  doi = {10.1161/circulationaha.124.070709}
}
Kostenlos starten →